Pulmonary vasodilation in acute and chronic heart failure: Empiricism and evidence

Current Heart Failure Reports

Volumn 8, Issue 3, 2011, Pages 219-225

  Guglin, Maya ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Bosentan; ENABLE trial; Endothelin; Endothelin antagonists; Heart failure; PASP; Phosphodiesterase inhibitors; Prostacyclin; Prostaglandin; Pulmonary artery; Pulmonary artery pressure; Pulmonary artery systolic pressure; Pulmonary capillary wedge pressure; Pulmonary hypertension; Pulmonary vascular resistance; REACH trial; RITZ trial; Sildenafil; Systemic vascular resistance; Tezosentan; Vasodilation; Vasodilator; VERITAS trial

Indexed keywords

BOSENTAN; DARUSENTAN; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; ILOPROST; INOTROPIC AGENT; MILRINONE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN E1; PROSTANOID; SILDENAFIL; TADALAFIL; TEZOSENTAN;

ACUTE HEART FAILURE; ARTICLE; CARDIOGENIC SHOCK; CARDIOMYOPATHY; CARDIOPULMONARY BYPASS; DIASTOLIC DYSFUNCTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DYSPNEA; ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; EXERCISE TOLERANCE; FLUSHING; FUNCTIONAL STATUS; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FILLING PRESSURE; HEART RIGHT VENTRICLE FAILURE; HEART VENTRICLE REMODELING; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; LIVER TOXICITY; LUNG ARTERY PRESSURE; LUNG EDEMA; LUNG VASCULAR RESISTANCE; MEAN ARTERIAL PRESSURE; METHEMOGLOBINEMIA; MORTALITY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; SIDE EFFECT; SUDDEN DEATH; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; VASODILATATION;

ACUTE DISEASE; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE INHIBITORS; PULMONARY CIRCULATION; VASCULAR RESISTANCE; VASODILATION; VASODILATOR AGENTS;

EID: 80055027156     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-011-0061-9     Document Type: Article

References (63)

1. Lam CS, Borlaug BA, Kane GC, et al. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation. 2009;119:2663-2670.
2. Guglin M. Diuretics as pathogenetic treatment for heart failure. Int J Gen Med. 2011;4:91-98.
3. Kjaergaard J, Akkan D, Iversen KK, et al. Right ventricular dysfunction as an independent predictor of short- and long-term mortality in patients with heart failure. Eur J Heart Fail. 2007;9:610-616. (Pubitemid 46702826)
4. Costard-Jackle A, Fowler MB. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol. 1992;19:48-54.
5. Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation. 2000;102:1718-1723.
6. Stewart DJ, Cernacek P, Costello KB, Rouleau JL. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation. 1992;85:510-517.
7. Cody RJ, Haas GJ, Binkley PF, et al. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85:504-509.
8. Ooi H, Colucci WS, Givertz MM. Endothelin mediates increased pulmonary vascular tone in patients with heart failure: demonstration by direct intrapulmonary infusion of sitaxsentan. Circulation. 2002;106:1618-1621.
9. Lucas M, Jasmin JF, Dupuis J. Effect of ET(A) receptor antagonist on pulmonary hypertension and vascular reactivity in rats with congestive heart failure. Pulm Pharmacol Ther. 2001;14:307-314. (Pubitemid 32625018)
10. Jiang BH, Tardif JC, Shi Y, Dupuis J. Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure. Eur Respir J. Perez-Villa F, Cuppoletti A, Rossel V, et al. Initial experience with bosentan therapy in patients considered ineligible for heart transplantation because of severe pulmonary hypertension. Clin Transplant. 2006;20:239-244.
11. Givertz MM, Colucci WS, LeJemtel TH, et al. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation. 2000;101:2922-2927. (Pubitemid 30415882)
12. Sutsch G, Kiowski W, Yan XW, et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation. 1998;98:2262-2268. (Pubitemid 28533844)
13. Cotter G, Kiowski W, Kaluski E, et al. Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure. Eur J Heart Fail. 2001;3:457-461. (Pubitemid 32780526)
14. Torre-Amione G, Young JB, Durand J, et al. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation. 2001;103:973-980. (Pubitemid 32183803)
15. Torre-Amione G, Durand JB, Nagueh S, et al. A pilot safety trial of prolonged (48 h) infusion of the dual endothelin-receptor antagonist tezosentan in patients with advanced heart failure. Chest. 2001;120:460-466. (Pubitemid 32881262)
16. Coletta AP, Cleland JG. Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology-WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. Eur J Heart Fail. 2001;3:747-750. (Pubitemid 33123176)
17. O'Connor CM, Gattis WA, Adams Jr KF, et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol. 2003;41:1452-1457. (Pubitemid 36543358)
18. Kaluski E, Kobrin I, Zimlichman R, et al. RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study. J Am Coll Cardiol. 2003;41:204-210. (Pubitemid 36092185)
19. Packer M, McMurray J, Massie BM, et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail. 2005;11:12-20. (Pubitemid 40215308)
20. McMurray JJ, Teerlink JR, Cotter G, et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA. 2007;298:2009-2019. (Pubitemid 350074798)
21. Rich S, McLaughlin VV. Endothelin receptor blockers in cardiovascular disease. Circulation. 2003;108:2184-2190. (Pubitemid 37363032)
22. Anand I, McMurray J, Cohn JN, et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:347-354.
23. Luscher TF, Enseleit F, Pacher R, et al. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation. 2002;106:2666-2672. (Pubitemid 35364920)
24. Kaluski E, Cotter G, Leitman M, et al. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension-a multi-center randomized study. Cardiology. 2008;109:273-280. (Pubitemid 351328923)
25. Hefke T, Zittermann A, Fuchs U, et al. Bosentan Effects on Hemodynamics and Clinical Outcome in Heart Failure Patients with Pulmonary Hypertension Awaiting Cardiac Transplantation. Thorac Cardiovasc Surg. 2011.
26. Hare JM, Loh E, Creager MA, Colucci WS. Nitric oxide inhibits the positive inotropic response to beta-adrenergic stimulation in humans with left ventricular dysfunction. Circulation. 1995;92:2198-2203.
27. Fagan KA, Tyler RC, Sato K, et al. Relative contributions of endothelial, inducible, and neuronal NOS to tone in the murine pulmonary circulation. Am J Physiol. 1999;277:L472-L478. (Pubitemid 29459666)
28. Cooper CJ, Landzberg MJ, Anderson TJ, et al. Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans. Circulation. 1996;93:266-271. (Pubitemid 26031484)
29. Ichinose F, Roberts Jr JD. Zapol WM: Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation. 2004;109:3106-3111.
30. Ardehali A, Hughes K, Sadeghi A, et al. Inhaled nitric oxide for pulmonary hypertension after heart transplantation. Transplantation. 2001;72:638-641. (Pubitemid 32802745)
31. Argenziano M, Choudhri AF, Moazami N, et al. Randomized, double-blind trial of inhaled nitric oxide in LVAD recipients with pulmonary hypertension. Ann Thorac Surg. 1998;65:340-345. (Pubitemid 28083325)
32. Hare JM, Shernan SK, Body SC, et al. Influence of inhaled nitric oxide on systemic flow and ventricular filling pressure in patients receiving mechanical circulatory assistance. Circulation. 1997;95:2250-2253. (Pubitemid 27191001)
33. Yui Y, Nakajima H, Kawai C, Murakami T. Prostacyclin therapy in patients with congestive heart failure. Am J Cardiol. 1982;50:320-324. (Pubitemid 12059027)
34. Haraldsson A, Kieler-Jensen N, Ricksten SE. Inhaled prostacyclin for treatment of pulmonary hypertension after cardiac surgery or heart transplantation: a pharmacodynamic study. J Cardiothorac Vasc Anesth. 1996;10:864-868. (Pubitemid 26422479)
35. Wittwer T, Pethig K, Struber M, et al. Aerosolized iloprost for severe pulmonary hypertension as a bridge to heart transplantation. Ann Thorac Surg. 2001;71:1004-1006. (Pubitemid 32210420)
36. Pacher R, Stanek B, Hulsmann M, et al. Prostaglandin E1-bridge to cardiac transplantation. Technique, dosage, results. Eur Heart J. 1997;18:318-329. (Pubitemid 27107594)
37. Rex S, Schaelte G, Metzelder S, et al. Inhaled iloprost to control pulmonary artery hypertension in patients undergoing mitral valve surgery: a prospective, randomized-controlled trial. Acta Anaesthesiol Scand. 2008;52:65-72.
38. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134:44-54. (Pubitemid 27329022)
39. Serra W, Musiari L, Ardissino D, et al. Benefit of prostaglandin infusion in severe heart failure Preliminary clinical experience of repetitive administration. Int J Cardiol. 2009.
40. Givertz MM, Hare JM, Loh E, et al. Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension. J Am Coll Cardiol. 1996;28:1775-1780. (Pubitemid 26426234)
41. Pamboukian SV, Carere RG, Webb JG, et al. The use of milrinone in pre-transplant assessment of patients with congestive heart failure and pulmonary hypertension. J Heart Lung Transplant. 1999;18:367-371. (Pubitemid 29205273)
42. Botha P, Parry G, Dark JH, Macgowan GA. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition. J Heart Lung Transplant. 2009;28:676-682.
43. Katz SD, Balidemaj K, Homma S, et al. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flowmediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol. 2000;36:845-851.
44. Hirata K, Adji A, Vlachopoulos C, O'Rourke MF. Effect of sildenafil on cardiac performance in patients with heart failure. Am J Cardiol. 2005;96:1436-1440. (Pubitemid 41566628)
45. Borlaug BA, Melenovsky V, Marhin T, et al. Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation. 2005;112:2642-2649. (Pubitemid 41532601)
46. Guazzi M, Tumminello G, Di Marco F, Guazzi MD. Influences of sildenafil on lung function and hemodynamics in patients with chronic heart failure. Clin Pharmacol Ther. 2004;76:371-378. (Pubitemid 39313128)
47. Lewis GD, Lachmann J, Camuso J, et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation. 2007;115:59-66. (Pubitemid 46058612)
48. Tedford RJ, Hemnes AR, Russell SD, et al. PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ Heart Fail. 2008;1:213-219.
49. Yin J, Kukucka M, Hoffmann J, et al. Sildenafil Preserves Lung Endothelial Function and Prevents Pulmonary Vascular Remodeling in a Rat Model of Diastolic Heart Failure. Circ Heart Fail.
50. Adamo CM, Dai DF, Percival JM, et al. Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy. Proc Natl Acad Sci USA. 2010;107:19079-19083.
51. Behling A, Rohde LE, Colombo FC, et al. Effects of 5'- phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebocontrolled clinical trial. J Card Fail. 2008;14:189-197. (Pubitemid 351444866)
52. Guazzi M, Casali M, Berti F, et al. Endothelium-mediated modulation of ergoreflex and improvement in exercise ventilation by acute sildenafil in heart failure patients. Clin Pharmacol Ther. 2008;83:336-341.
53. Guazzi M, Arena R, Pinkstaff S, Guazzi MD. Six months of Sildenafil therapy improves heart rate recovery in patients with heart failure. Int J Cardiol. 2008.
54. Guazzi M, Samaja M, Arena R, et al. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol. 2007;50:2136-2144. (Pubitemid 350117342)
55. Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007;116:1555-1562. (Pubitemid 47511419)
56. Al-Hiti H, Melenovsky V, Syrovatka P, et al. Sildenafil is more selective pulmonary vasodilator than prostaglandin E(1) in patients with pulmonary hypertension due to heart failure. Physiol Res.
57. Zakliczynski M, Maruszewski M, Pyka L, et al. Effectiveness and safety of treatment with sildenafil for secondary pulmonary hypertension in heart transplant candidates. Transplant Proc. 2007;39:2856-2858. (Pubitemid 350088099)
58. Maruszewski M, Zakliczynski M, Przybylski R, et al. Use of sildenafil in heart transplant recipients with pulmonary hypertension may prevent right heart failure. Transplant Proc. 2007;39:2850-2852. (Pubitemid 350088106)
59. Boffini M, Sansone F, Ceresa F, et al. Role of oral sildenafil in the treatment of right ventricular dysfunction after heart transplantation. Transplant Proc. 2009;41:1353-1356.
60. Klodell Jr CT, Morey TE, Lobato EB, et al. Effect of sildenafil on pulmonary artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devices. Ann Thorac Surg. 2007;83:68-71. discussion. (Pubitemid 44917910)
61. Stehlik J, Movsesian MA. Combined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure. J Card Fail. 2009;15:31-34.
62. Parker JD, Bart BA, Webb DJ, et al. Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial. Crit Care Med. 2007;35:1863-1868. (Pubitemid 47220359)
63. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 4:8-17.